JP2001521908A - ワクチンアジュバントとして有用な封入された免疫調節物質 - Google Patents

ワクチンアジュバントとして有用な封入された免疫調節物質

Info

Publication number: JP2001521908A
Authority: JP; Japan
Prior art keywords: composition; immunomodulator; encapsulated; polypeptide; vaccine
Prior art date: 1997-10-31
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

JP2000518694A

Other languages

English (en)

Japanese (ja)

Inventor

リチャードエス．ドンデロ

ブルースシー．ギャルトン

レスリーエス．ケイシー

Original Assignee

シストロンバイオテクノロジーインク．

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-10-31

Filing date

1998-11-02

Publication date

2001-11-13

1998-11-02 Application filed by シストロンバイオテクノロジーインク． filed Critical シストロンバイオテクノロジーインク．

2001-11-13 Publication of JP2001521908A publication Critical patent/JP2001521908A/ja

Status Pending legal-status Critical Current

Links

239000002955 immunomodulating agent Substances 0.000 title claims abstract description 46
229940121354 immunomodulator Drugs 0.000 title claims abstract description 46
239000012646 vaccine adjuvant Substances 0.000 title description 2
229940124931 vaccine adjuvant Drugs 0.000 title description 2
239000000203 mixture Substances 0.000 claims abstract description 54
229960005486 vaccine Drugs 0.000 claims abstract description 41
230000002584 immunomodulator Effects 0.000 claims abstract description 36
108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 25
102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 23
241001465754 Metazoa Species 0.000 claims abstract description 22
239000011159 matrix material Substances 0.000 claims abstract description 20
239000000427 antigen Substances 0.000 claims abstract description 19
108091007433 antigens Proteins 0.000 claims abstract description 19
102000036639 antigens Human genes 0.000 claims abstract description 19
230000028993 immune response Effects 0.000 claims abstract description 13
241000700605 Viruses Species 0.000 claims abstract description 9
230000000890 antigenic effect Effects 0.000 claims abstract description 7
230000002238 attenuated effect Effects 0.000 claims abstract description 6
238000000034 method Methods 0.000 claims description 35
238000005538 encapsulation Methods 0.000 claims description 17
229920001184 polypeptide Polymers 0.000 claims description 17
239000002502 liposome Substances 0.000 claims description 15
230000002163 immunogen Effects 0.000 claims description 13
108010002350 Interleukin-2 Proteins 0.000 claims description 7
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical group CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 6
229920000249 biocompatible polymer Polymers 0.000 claims description 5
239000012634 fragment Substances 0.000 claims description 5
150000001413 amino acids Chemical group 0.000 claims description 4
RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 claims description 3
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 3
108060003951 Immunoglobulin Proteins 0.000 claims description 3
108010065805 Interleukin-12 Proteins 0.000 claims description 3
108090000978 Interleukin-4 Proteins 0.000 claims description 3
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 3
235000013922 glutamic acid Nutrition 0.000 claims description 3
239000004220 glutamic acid Substances 0.000 claims description 3
102000018358 immunoglobulin Human genes 0.000 claims description 3
239000004310 lactic acid Substances 0.000 claims description 3
235000014655 lactic acid Nutrition 0.000 claims description 3
238000010255 intramuscular injection Methods 0.000 claims description 2
239000007927 intramuscular injection Substances 0.000 claims description 2
238000010254 subcutaneous injection Methods 0.000 claims description 2
239000007929 subcutaneous injection Substances 0.000 claims description 2
230000008685 targeting Effects 0.000 claims 4
102000018713 Histocompatibility Antigens Class II Human genes 0.000 claims 2
108010027412 Histocompatibility Antigens Class II Proteins 0.000 claims 2
239000002671 adjuvant Substances 0.000 abstract description 18
239000000126 substance Substances 0.000 abstract description 10
102000004127 Cytokines Human genes 0.000 abstract description 3
108090000695 Cytokines Proteins 0.000 abstract description 3
102000008072 Lymphokines Human genes 0.000 abstract 2
108010074338 Lymphokines Proteins 0.000 abstract 2
208000037797 influenza A Diseases 0.000 description 8
235000018102 proteins Nutrition 0.000 description 8
102000004169 proteins and genes Human genes 0.000 description 8
229940079593 drug Drugs 0.000 description 7
239000003814 drug Substances 0.000 description 7
239000002243 precursor Substances 0.000 description 7
108010076504 Protein Sorting Signals Proteins 0.000 description 6
210000004027 cell Anatomy 0.000 description 6
108090000623 proteins and genes Proteins 0.000 description 6
102000000588 Interleukin-2 Human genes 0.000 description 5
210000000612 antigen-presenting cell Anatomy 0.000 description 5
238000009472 formulation Methods 0.000 description 5
230000014616 translation Effects 0.000 description 5
108010063738 Interleukins Proteins 0.000 description 4
102000015696 Interleukins Human genes 0.000 description 4
230000004071 biological effect Effects 0.000 description 4
150000001875 compounds Chemical class 0.000 description 4
210000000987 immune system Anatomy 0.000 description 4
238000002360 preparation method Methods 0.000 description 4
150000003839 salts Chemical group 0.000 description 4
230000009885 systemic effect Effects 0.000 description 4
108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
101001033249 Homo sapiens Interleukin-1 beta Proteins 0.000 description 3
239000000232 Lipid Bilayer Substances 0.000 description 3
239000004480 active ingredient Substances 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
239000008280 blood Substances 0.000 description 3
239000002552 dosage form Substances 0.000 description 3
230000003053 immunization Effects 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
239000012528 membrane Substances 0.000 description 3
210000001616 monocyte Anatomy 0.000 description 3
BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 description 3
239000000546 pharmaceutical excipient Substances 0.000 description 3
230000008569 process Effects 0.000 description 3
239000000243 solution Substances 0.000 description 3
239000000829 suppository Substances 0.000 description 3
238000012360 testing method Methods 0.000 description 3
238000013519 translation Methods 0.000 description 3
102000011767 Acute-Phase Proteins Human genes 0.000 description 2
108010062271 Acute-Phase Proteins Proteins 0.000 description 2
241000282412 Homo Species 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
108010093096 Immobilized Enzymes Proteins 0.000 description 2
108010058683 Immobilized Proteins Proteins 0.000 description 2
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
241000700159 Rattus Species 0.000 description 2
230000004913 activation Effects 0.000 description 2
210000003719 b-lymphocyte Anatomy 0.000 description 2
230000037396 body weight Effects 0.000 description 2
238000000576 coating method Methods 0.000 description 2
230000000694 effects Effects 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
230000002209 hydrophobic effect Effects 0.000 description 2
230000036039 immunity Effects 0.000 description 2
230000001965 increasing effect Effects 0.000 description 2
206010022000 influenza Diseases 0.000 description 2
229940047122 interleukins Drugs 0.000 description 2
210000004698 lymphocyte Anatomy 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
239000000463 material Substances 0.000 description 2
230000035800 maturation Effects 0.000 description 2
229920000642 polymer Polymers 0.000 description 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
238000001243 protein synthesis Methods 0.000 description 2
102220240796 rs553605556 Human genes 0.000 description 2
230000004936 stimulating effect Effects 0.000 description 2
230000000638 stimulation Effects 0.000 description 2
239000000725 suspension Substances 0.000 description 2
238000013268 sustained release Methods 0.000 description 2
239000012730 sustained-release form Substances 0.000 description 2
238000007910 systemic administration Methods 0.000 description 2
GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
MIJDSYMOBYNHOT-UHFFFAOYSA-N 2-(ethylamino)ethanol Chemical compound CCNCCO MIJDSYMOBYNHOT-UHFFFAOYSA-N 0.000 description 1
WPWUFUBLGADILS-WDSKDSINSA-N Ala-Pro Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(O)=O WPWUFUBLGADILS-WDSKDSINSA-N 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
208000006386 Bone Resorption Diseases 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
102000009016 Cholera Toxin Human genes 0.000 description 1
108010049048 Cholera Toxin Proteins 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
238000002965 ELISA Methods 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
102000009109 Fc receptors Human genes 0.000 description 1
108010087819 Fc receptors Proteins 0.000 description 1
241000233866 Fungi Species 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
108010002352 Interleukin-1 Proteins 0.000 description 1
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
102000043131 MHC class II family Human genes 0.000 description 1
108091054438 MHC class II family Proteins 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
206010028813 Nausea Diseases 0.000 description 1
108010058846 Ovalbumin Proteins 0.000 description 1
108010033276 Peptide Fragments Proteins 0.000 description 1
102000007079 Peptide Fragments Human genes 0.000 description 1
108010038988 Peptide Hormones Proteins 0.000 description 1
102000015731 Peptide Hormones Human genes 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
206010037660 Pyrexia Diseases 0.000 description 1
IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
230000024932 T cell mediated immunity Effects 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
239000002253 acid Substances 0.000 description 1
108010087924 alanylproline Proteins 0.000 description 1
230000004075 alteration Effects 0.000 description 1
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
DIZPMCHEQGEION-UHFFFAOYSA-H aluminium sulfate (anhydrous) Chemical compound [Al+3].[Al+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O DIZPMCHEQGEION-UHFFFAOYSA-H 0.000 description 1
235000001014 amino acid Nutrition 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
210000004102 animal cell Anatomy 0.000 description 1
230000008901 benefit Effects 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000000975 bioactive effect Effects 0.000 description 1
229920001222 biopolymer Polymers 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
230000024279 bone resorption Effects 0.000 description 1
239000000872 buffer Substances 0.000 description 1
210000004899 c-terminal region Anatomy 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000002775 capsule Substances 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
239000000969 carrier Substances 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
230000008859 change Effects 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
238000013270 controlled release Methods 0.000 description 1
230000001276 controlling effect Effects 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
210000004443 dendritic cell Anatomy 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
238000009826 distribution Methods 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
210000002472 endoplasmic reticulum Anatomy 0.000 description 1
210000002889 endothelial cell Anatomy 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
230000028023 exocytosis Effects 0.000 description 1
230000014509 gene expression Effects 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
210000003494 hepatocyte Anatomy 0.000 description 1
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
230000013632 homeostatic process Effects 0.000 description 1
230000028996 humoral immune response Effects 0.000 description 1
238000002649 immunization Methods 0.000 description 1
230000005847 immunogenicity Effects 0.000 description 1
230000016784 immunoglobulin production Effects 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
230000006698 induction Effects 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
150000007529 inorganic bases Chemical class 0.000 description 1
229910052742 iron Inorganic materials 0.000 description 1
235000014413 iron hydroxide Nutrition 0.000 description 1
NCNCGGDMXMBVIA-UHFFFAOYSA-L iron(ii) hydroxide Chemical compound [OH-].[OH-].[Fe+2] NCNCGGDMXMBVIA-UHFFFAOYSA-L 0.000 description 1
JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
239000008101 lactose Substances 0.000 description 1
210000001821 langerhans cell Anatomy 0.000 description 1
239000006193 liquid solution Substances 0.000 description 1
239000006194 liquid suspension Substances 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
239000001095 magnesium carbonate Substances 0.000 description 1
229910000021 magnesium carbonate Inorganic materials 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
206010025482 malaise Diseases 0.000 description 1
229960002510 mandelic acid Drugs 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000008693 nausea Effects 0.000 description 1
230000000955 neuroendocrine Effects 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
150000007530 organic bases Chemical class 0.000 description 1
229940092253 ovalbumin Drugs 0.000 description 1
239000006179 pH buffering agent Substances 0.000 description 1
244000045947 parasite Species 0.000 description 1
239000000813 peptide hormone Substances 0.000 description 1
210000001539 phagocyte Anatomy 0.000 description 1
230000001766 physiological effect Effects 0.000 description 1
239000006187 pill Substances 0.000 description 1
229920001281 polyalkylene Polymers 0.000 description 1
230000030393 positive regulation of fibroblast proliferation Effects 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000000843 powder Substances 0.000 description 1
MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
229960004919 procaine Drugs 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
150000003180 prostaglandins Chemical class 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000007909 solid dosage form Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
241000894007 species Species 0.000 description 1
238000013223 sprague-dawley female rat Methods 0.000 description 1
239000010421 standard material Substances 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
239000003826 tablet Substances 0.000 description 1
229960000814 tetanus toxoid Drugs 0.000 description 1
230000002992 thymic effect Effects 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
239000003053 toxin Substances 0.000 description 1
231100000765 toxin Toxicity 0.000 description 1
108700012359 toxins Proteins 0.000 description 1
150000003626 triacylglycerols Chemical class 0.000 description 1
210000004881 tumor cell Anatomy 0.000 description 1
210000000605 viral structure Anatomy 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
238000009736 wetting Methods 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1
239000011701 zinc Substances 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2006—IL-1
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A61K2039/55527—Interleukins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A61K2039/55527—Interleukins
- A61K2039/55533—IL-2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A61K2039/55527—Interleukins
- A61K2039/55538—IL-12
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Immunology (AREA)
Chemical Kinetics & Catalysis (AREA)
Microbiology (AREA)
Oncology (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Virology (AREA)
Communicable Diseases (AREA)
Mycology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Dispersion Chemistry (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicinal Preparation (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)

JP2000518694A 1997-10-31 1998-11-02 ワクチンアジュバントとして有用な封入された免疫調節物質 Pending JP2001521908A (ja)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US96240797A	1997-10-31	1997-10-31
US08/962,407		1997-10-31
PCT/US1998/023313 WO1999022763A2 (en)	1997-10-31	1998-11-02	Encapsulated immunomodulators useful as vaccine adjuvants

Publications (1)

Publication Number	Publication Date
JP2001521908A true JP2001521908A (ja)	2001-11-13

Family

ID=25505819

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2000518694A Pending JP2001521908A (ja)	1997-10-31	1998-11-02	ワクチンアジュバントとして有用な封入された免疫調節物質

Country Status (6)

Country	Link
EP (1)	EP1027071A2 (de)
JP (1)	JP2001521908A (de)
AU (1)	AU1208499A (de)
CA (1)	CA2307541A1 (de)
IL (1)	IL135480A0 (de)
WO (1)	WO1999022763A2 (de)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2009510031A (ja) *	2005-09-30	2009-03-12	リポクセンテクノロジーズリミテッド	多糖抗原及びタンパク質アジュバントを含むリポソームワクチン組成物
JP2011506334A (ja) *	2007-12-07	2011-03-03	ノバルティスアーゲー	免疫応答を誘導するための組成物

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2005220156B2 (en) *	2004-02-27	2011-06-02	Vaxconsulting	Peptides of IL1 beta and TNF alpha and method of treatment using same

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP3002213B2 (ja) *	1989-11-29	2000-01-24	帝国臓器製薬株式会社	ペプチドおよびこのペプチドを含有する薬剤
EP0604727A1 (de) *	1992-12-31	1994-07-06	American Cyanamid Company	Verbesserte Immunogenizität einer Vakzine durch Inkorporieren eines Zytokines in einen immun-stimulierenden Komplex, der ein Antigen enthält
US5919480A (en) *	1996-06-24	1999-07-06	Yissum Research Development Company Of The Hebrew University Of Jerusalem	Liposomal influenza vaccine composition and method

1998
- 1998-11-02 WO PCT/US1998/023313 patent/WO1999022763A2/en not_active Ceased
- 1998-11-02 CA CA002307541A patent/CA2307541A1/en not_active Abandoned
- 1998-11-02 IL IL13548098A patent/IL135480A0/xx not_active IP Right Cessation
- 1998-11-02 AU AU12084/99A patent/AU1208499A/en not_active Abandoned
- 1998-11-02 JP JP2000518694A patent/JP2001521908A/ja active Pending
- 1998-11-02 EP EP98955231A patent/EP1027071A2/de not_active Withdrawn

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2009510031A (ja) *	2005-09-30	2009-03-12	リポクセンテクノロジーズリミテッド	多糖抗原及びタンパク質アジュバントを含むリポソームワクチン組成物
JP2011506334A (ja) *	2007-12-07	2011-03-03	ノバルティスアーゲー	免疫応答を誘導するための組成物
JP2014159486A (ja) *	2007-12-07	2014-09-04	Novartis Ag	免疫応答を誘導するための組成物

Also Published As

Publication number	Publication date
WO1999022763A2 (en)	1999-05-14
CA2307541A1 (en)	1999-05-14
AU1208499A (en)	1999-05-24
IL135480A0 (en)	2001-05-20
EP1027071A2 (de)	2000-08-16
WO1999022763A3 (en)	1999-08-05

Publication	Publication Date	Title
RU2118164C1 (ru)	1998-08-27	Вакцинная композиция, обладающая свойством вызывать цитолитический т-клеточный ответ у млекопитающих, способ получения цитолитического т-клеточного ответа in vivo, способ получения вакцины
Tsuji et al.	1997	Immunomodulatory effects of a plasmid expressing B7‐2 on human immunodeficiency virus‐1‐specific cell‐mediated immunity induced by a plasmid encoding the viral antigen
US8735357B2 (en)	2014-05-27	Method of inducing antigen-specific T cells
JP5519477B2 (ja)	2014-06-11	Ｔ１免疫応答とｔ２免疫応答との間で調節するためのワクチン
US20050002951A1 (en)	2005-01-06	Novel method of inducing antigen-specific t cells
KR20070094663A (ko)	2007-09-20	적합성이 높은 담체에 의한 경비 수송／면역화
JP2004506019A (ja)	2004-02-26	少なくとも１つの抗原およびカテリシジン由来の抗菌ペプチドまたはその誘導体を含むワクチン
TW200307557A (en)	2003-12-16	Stabilized synthetic immunogen delivery systems
JPH09503742A (ja)	1997-04-15	ワクチン用免疫原性ｌｈｒｈペプチド構築体および合成普遍免疫刺激器
AU2013255860A1 (en)	2014-12-11	Compositions
CA2206778A1 (en)	1996-06-27	Peptides having immunomodulatory activity
CA2372181A1 (en)	2000-11-23	Adjuvant combination formulations
JP2002518343A (ja)	2002-06-25	ヘリコバクター感染に対する非経口的免疫処置法におけるｌｔおよびｃｔ
JPH05504756A (ja)	1993-07-22	免疫刺激性を有する組成物と、そのヒトと獣医学用医薬への応用
JP2001521908A (ja)	2001-11-13	ワクチンアジュバントとして有用な封入された免疫調節物質
MXPA06009805A (es)	2007-04-02	Peptidos de interleucina 1 beta y factor de necrosis tumoral alfa y metodo de tratamiento utilizando los mismos.
JP2001089389A (ja)	2001-04-03	抗原特異的ｔ細胞の誘導剤
US6355256B1 (en)	2002-03-12	Compositions containing a p53 derived protein or peptide, an adjuvant, and interleukin-12 and uses thereof
KR20070048140A (ko)	2007-05-08	온코세르카 볼불러스의 천연 생성물의 항원보강성 및 면역강화 특성
AU2003200723B2 (en)	2006-07-27	Encapsulated immunomodulators useful as vaccine adjuvants
US6887484B2 (en)	2005-05-03	Vaccine composition containing a promoter peptide
MXPA05002699A (es)	2005-09-20	Inmunizacion contra grelina autologa.
US20070053923A1 (en)	2007-03-08	Dna vaccine composition with enhanced immunogenicity
JP2008521871A (ja)	2008-06-26	ホスファチジルセリンおよび抗原またはアレルゲンを含む組成物、およびその使用
Nikou et al.	2005	A HER-2/neu peptide admixed with PLA microspheres induces a Th1-biased immune response in mice